Barclays’s Immunogen Inc IMGN Stock Holding History

Barclays’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,800	Closed	-$36K	–	5758
2021 Q4	$36K	Buy	+4,800	New	+$29.8K	﹤0.01%	3881
2019 Q2	–	Sell	-57,500	Closed	-$156K	–	7372
2019 Q1	$156K	Buy	+57,500	New	+$249K	﹤0.01%	5016
2018 Q3	–	Sell	-286,400	Closed	-$2.79M	–	7471
2018 Q2	$2.79M	Buy	+286,400	New	+$3.02M	﹤0.01%	2258
2016 Q3	–	Sell	-91,600	Closed	-$282K	–	6851
2016 Q2	$282K	Buy	+91,600	New	+$574K	﹤0.01%	3671

Other funds holding IMGN

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's IMGN Position: Q1 2024 in Review

Barclays sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 642,156 shares — an estimated $19M sold.

Barclays first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $19M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

Barclays reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
Barclays sold 642,156 Immunogen Inc shares in Q1 2024, an estimated $19M.
Barclays first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
Barclays's Immunogen Inc position peaked at $19M in Q4 2023.
3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.